These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 30522890)

  • 21. Utility of physiologically based pharmacokinetic modeling to predict inter-antibody variability in monoclonal antibody pharmacokinetics in mice.
    Liu S; Humphreys SC; Cook KD; Conner KP; Correia AR; Jacobitz AW; Yang M; Primack R; Soto M; Padaki R; Lubomirski M; Smith R; Mock M; Thomas VA
    MAbs; 2023; 15(1):2263926. PubMed ID: 37824334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
    Cao Y; Balthasar JP; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.
    Ren HC; Sai Y; Chen T
    Eur J Drug Metab Pharmacokinet; 2019 Feb; 44(1):121-132. PubMed ID: 30039459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
    Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system.
    Chang HY; Wu S; Chowdhury EA; Shah DK
    J Pharmacokinet Pharmacodyn; 2022 Jun; 49(3):337-362. PubMed ID: 35092540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologically based pharmacokinetic (PBPK) modeling and simulation in neonatal drug development: how clinicians can contribute.
    Smits A; De Cock P; Vermeulen A; Allegaert K
    Expert Opin Drug Metab Toxicol; 2019 Jan; 15(1):25-34. PubMed ID: 30554542
    [No Abstract]   [Full Text] [Related]  

  • 27. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
    Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
    J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
    Peters SA; Ungell AL; Dolgos H
    Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies.
    Malik P; Edginton A
    Expert Opin Drug Metab Toxicol; 2018 Jun; 14(6):585-599. PubMed ID: 29806953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-pore physiologically based pharmacokinetic model with de novo derived parameters for predicting plasma PK of different size protein therapeutics.
    Li Z; Shah DK
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):305-318. PubMed ID: 31028591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.
    Jones HM; Mayawala K; Poulin P
    AAPS J; 2013 Apr; 15(2):377-87. PubMed ID: 23269526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.
    Ovacik M; Lin K
    Clin Transl Sci; 2018 Nov; 11(6):540-552. PubMed ID: 29877608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
    Bussing D; K Shah D
    J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
    Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
    Heiskanen T; Heiskanen T; Kairemo K
    Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of altered endogenous IgG on unspecific mAb clearance.
    Fuhrmann S; Kloft C; Huisinga W
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):351-374. PubMed ID: 28439684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.